Do analysts prefer TVRD or REVB?

Tvardi Therapeutics presently has a consensus price target of $18.00, suggesting a potential upside of 911.24%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tvardi Therapeutics is more favorable than Revelation Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tvardi Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78 Revelation Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TVRD or REVB more profitable?

Revelation Biosciences' return on equity of -100.19% beat Tvardi Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tvardi Therapeutics N/A -145.40% -91.11% Revelation Biosciences N/A -100.19% -82.72%

Does the media refer more to TVRD or REVB?

In the previous week, Tvardi Therapeutics had 6 more articles in the media than Revelation Biosciences. MarketBeat recorded 7 mentions for Tvardi Therapeutics and 1 mentions for Revelation Biosciences. Tvardi Therapeutics' average media sentiment score of 0.71 beat Revelation Biosciences' score of 0.00 indicating that Tvardi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tvardi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revelation Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, CTXR or REVB?

Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Citius Pharmaceuticals N/A N/A -$37.43M -$1.67 N/A Revelation Biosciences N/A N/A -$8.91M -$12.31 N/A

Is CTXR or REVB more profitable?

Citius Pharmaceuticals' return on equity of -59.57% beat Revelation Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Citius Pharmaceuticals N/A -59.57% -34.47% Revelation Biosciences N/A -100.19% -82.72%

Does the media prefer CTXR or REVB?

In the previous week, Citius Pharmaceuticals had 9 more articles in the media than Revelation Biosciences. MarketBeat recorded 10 mentions for Citius Pharmaceuticals and 1 mentions for Revelation Biosciences. Revelation Biosciences' average media sentiment score of 0.00 beat Citius Pharmaceuticals' score of -0.70 indicating that Revelation Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Citius Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Revelation Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend LPCN or REVB?

Lipocine currently has a consensus target price of $15.00, suggesting a potential upside of 628.16%. Given Lipocine's stronger consensus rating and higher probable upside, equities analysts clearly believe Lipocine is more favorable than Revelation Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipocine 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Revelation Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to LPCN or REVB?

In the previous week, Lipocine and Lipocine both had 1 articles in the media. Lipocine's average media sentiment score of 0.75 beat Revelation Biosciences' score of 0.00 indicating that Lipocine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lipocine 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revelation Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer REVB or MDCX?

Medicus Pharma has a consensus price target of $9.00, suggesting a potential upside of 3,396.50%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Medicus Pharma is more favorable than Revelation Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revelation Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Medicus Pharma 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has stronger earnings and valuation, REVB or MDCX?

Medicus Pharma is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Revelation Biosciences N/A N/A -$8.91M -$12.31 N/A Medicus Pharma N/A N/A -$35.46M -$2.46 N/A

Is REVB or MDCX more profitable?

Revelation Biosciences' return on equity of -100.19% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Revelation Biosciences N/A -100.19% -82.72% Medicus Pharma N/A -3,137.84% -263.24%

Does the media refer more to REVB or MDCX?

In the previous week, Medicus Pharma had 5 more articles in the media than Revelation Biosciences. MarketBeat recorded 6 mentions for Medicus Pharma and 1 mentions for Revelation Biosciences. Revelation Biosciences' average media sentiment score of 0.00 beat Medicus Pharma's score of -0.71 indicating that Revelation Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revelation Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Medicus Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Do analysts recommend REVB or ZIVO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revelation Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is REVB or ZIVO more profitable?

ZIVO Bioscience's return on equity of 0.00% beat Revelation Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Revelation Biosciences N/A -100.19% -82.72% ZIVO Bioscience N/A N/A -2,240.92%

Revelation Biosciences (REVB) Competitors

$1.10 +0.01 (+0.92%)

Closing price 08/24/2026 03:58 PM Eastern

Extended Trading

$1.10 0.00 (0.00%)

As of 06:23 AM Eastern

Compare

REVB vs. TVRD, CTXR, LPCN, MDCX, and ZIVO

Should you buy Revelation Biosciences stock or one of its competitors? Revelation Biosciences's main competitors and comparable companies include Tvardi Therapeutics (TVRD), Citius Pharmaceuticals (CTXR), Lipocine (LPCN), Medicus Pharma (MDCX), and ZIVO Bioscience (ZIVO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Revelation Biosciences compare to Tvardi Therapeutics?

Tvardi Therapeutics (NASDAQ:TVRD) and Revelation Biosciences (NASDAQ:REVB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

44.7% of Tvardi Therapeutics shares are held by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are held by institutional investors. 7.4% of Tvardi Therapeutics shares are held by company insiders. Comparatively, 4.8% of Revelation Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Tvardi Therapeutics presently has a consensus price target of $18.00, suggesting a potential upside of 911.24%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tvardi Therapeutics is more favorable than Revelation Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Revelation Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Revelation Biosciences has lower revenue, but higher earnings than Tvardi Therapeutics. Tvardi Therapeutics is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tvardi Therapeutics	$7.14M	3.33	-$18.21M	-$2.79	N/A
Revelation Biosciences	N/A	N/A	-$8.91M	-$12.31	N/A

In the previous week, Tvardi Therapeutics had 6 more articles in the media than Revelation Biosciences. MarketBeat recorded 7 mentions for Tvardi Therapeutics and 1 mentions for Revelation Biosciences. Tvardi Therapeutics' average media sentiment score of 0.71 beat Revelation Biosciences' score of 0.00 indicating that Tvardi Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tvardi Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revelation Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Revelation Biosciences' return on equity of -100.19% beat Tvardi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	N/A	-145.40%	-91.11%
Revelation Biosciences	N/A	-100.19%	-82.72%

Tvardi Therapeutics has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market. Comparatively, Revelation Biosciences has a beta of -0.15, indicating that its stock price is 115% less volatile than the broader market.

Summary

Tvardi Therapeutics beats Revelation Biosciences on 11 of the 15 factors compared between the two stocks.

How does Revelation Biosciences compare to Citius Pharmaceuticals?

Citius Pharmaceuticals (NASDAQ:CTXR) and Revelation Biosciences (NASDAQ:REVB) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Citius Pharmaceuticals' return on equity of -59.57% beat Revelation Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Pharmaceuticals	N/A	-59.57%	-34.47%
Revelation Biosciences	N/A	-100.19%	-82.72%

Citius Pharmaceuticals has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market. Comparatively, Revelation Biosciences has a beta of -0.15, meaning that its stock price is 115% less volatile than the broader market.

Citius Pharmaceuticals currently has a consensus target price of $5.00, suggesting a potential upside of 768.96%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Citius Pharmaceuticals is more favorable than Revelation Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Revelation Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

16.9% of Citius Pharmaceuticals shares are held by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are held by institutional investors. 5.0% of Citius Pharmaceuticals shares are held by company insiders. Comparatively, 4.8% of Revelation Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$1.67	N/A
Revelation Biosciences	N/A	N/A	-$8.91M	-$12.31	N/A

In the previous week, Citius Pharmaceuticals had 9 more articles in the media than Revelation Biosciences. MarketBeat recorded 10 mentions for Citius Pharmaceuticals and 1 mentions for Revelation Biosciences. Revelation Biosciences' average media sentiment score of 0.00 beat Citius Pharmaceuticals' score of -0.70 indicating that Revelation Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Citius Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Revelation Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Citius Pharmaceuticals beats Revelation Biosciences on 10 of the 13 factors compared between the two stocks.

How does Revelation Biosciences compare to Lipocine?

Lipocine (NASDAQ:LPCN) and Revelation Biosciences (NASDAQ:REVB) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Revelation Biosciences has a net margin of 0.00% compared to Lipocine's net margin of -755.39%. Lipocine's return on equity of -64.75% beat Revelation Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipocine	-755.39%	-64.75%	-57.62%
Revelation Biosciences	N/A	-100.19%	-82.72%

Lipocine currently has a consensus target price of $15.00, suggesting a potential upside of 628.16%. Given Lipocine's stronger consensus rating and higher probable upside, equities analysts clearly believe Lipocine is more favorable than Revelation Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Revelation Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

9.1% of Lipocine shares are owned by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are owned by institutional investors. 4.7% of Lipocine shares are owned by insiders. Comparatively, 4.8% of Revelation Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Lipocine and Lipocine both had 1 articles in the media. Lipocine's average media sentiment score of 0.75 beat Revelation Biosciences' score of 0.00 indicating that Lipocine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lipocine	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revelation Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lipocine has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market. Comparatively, Revelation Biosciences has a beta of -0.15, suggesting that its stock price is 115% less volatile than the broader market.

Revelation Biosciences has lower revenue, but higher earnings than Lipocine. Lipocine is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$1.98M	8.57	-$9.63M	-$1.79	N/A
Revelation Biosciences	N/A	N/A	-$8.91M	-$12.31	N/A

Summary

Lipocine beats Revelation Biosciences on 8 of the 13 factors compared between the two stocks.

How does Revelation Biosciences compare to Medicus Pharma?

Revelation Biosciences (NASDAQ:REVB) and Medicus Pharma (NASDAQ:MDCX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

Medicus Pharma is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revelation Biosciences	N/A	N/A	-$8.91M	-$12.31	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.46	N/A

Revelation Biosciences' return on equity of -100.19% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revelation Biosciences	N/A	-100.19%	-82.72%
Medicus Pharma	N/A	-3,137.84%	-263.24%

12.8% of Revelation Biosciences shares are owned by institutional investors. 4.8% of Revelation Biosciences shares are owned by company insiders. Comparatively, 8.1% of Medicus Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Revelation Biosciences has a beta of -0.15, meaning that its share price is 115% less volatile than the broader market. Comparatively, Medicus Pharma has a beta of 0.12, meaning that its share price is 88% less volatile than the broader market.

In the previous week, Medicus Pharma had 5 more articles in the media than Revelation Biosciences. MarketBeat recorded 6 mentions for Medicus Pharma and 1 mentions for Revelation Biosciences. Revelation Biosciences' average media sentiment score of 0.00 beat Medicus Pharma's score of -0.71 indicating that Revelation Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revelation Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medicus Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Medicus Pharma has a consensus price target of $9.00, suggesting a potential upside of 3,396.50%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Medicus Pharma is more favorable than Revelation Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revelation Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Medicus Pharma beats Revelation Biosciences on 7 of the 13 factors compared between the two stocks.

How does Revelation Biosciences compare to ZIVO Bioscience?

Revelation Biosciences (NASDAQ:REVB) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

12.8% of Revelation Biosciences shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 4.8% of Revelation Biosciences shares are held by insiders. Comparatively, 48.9% of ZIVO Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revelation Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Revelation Biosciences had 1 more articles in the media than ZIVO Bioscience. MarketBeat recorded 1 mentions for Revelation Biosciences and 0 mentions for ZIVO Bioscience. Revelation Biosciences' average media sentiment score of 0.00 equaled ZIVO Bioscience'saverage media sentiment score.

Company	Overall Sentiment
Revelation Biosciences	Neutral
ZIVO Bioscience	Neutral

Revelation Biosciences has a beta of -0.15, indicating that its stock price is 115% less volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.14, indicating that its stock price is 86% less volatile than the broader market.

ZIVO Bioscience has higher revenue and earnings than Revelation Biosciences. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revelation Biosciences	N/A	N/A	-$8.91M	-$12.31	N/A
ZIVO Bioscience	$15.85K	1,135.52	-$7.78M	-$1.40	N/A

ZIVO Bioscience's return on equity of 0.00% beat Revelation Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revelation Biosciences	N/A	-100.19%	-82.72%
ZIVO Bioscience	N/A	N/A	-2,240.92%

Summary

ZIVO Bioscience beats Revelation Biosciences on 7 of the 11 factors compared between the two stocks.

Get Revelation Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding REVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

REVB vs. The Competition

Export

Metric	Revelation Biosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.34M	$12.54B	$7.36B	$12.81B
Dividend Yield	N/A	2.62%	2.54%	10.78%
P/E Ratio	-0.09	780.42	270.58	24.05
Price / Sales	N/A	758.65	641.07	105.04
Price / Cash	N/A	15.47	29.03	36.89
Price / Book	0.86	10.45	11.22	6.40
Net Income	-$8.91M	$2.79B	$3.46B	$347.95M
7 Day Performance	-0.90%	1.83%	1.72%	1.48%
1 Month Performance	3.77%	4.72%	7.32%	5.13%
1 Year Performance	-90.35%	7.73%	26.12%	17.00%

Revelation Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
REVB Revelation Biosciences	0.5388 of 5 stars	$1.10 +0.9%	N/A	-90.6%	$4.34M	N/A	N/A	10
TVRD Tvardi Therapeutics	3.8555 of 5 stars	$1.88 -1.1%	$18.00 +857.4%	-93.7%	$17.63M	$7.14M	N/A	80	Analyst Upgrade
CTXR Citius Pharmaceuticals	2.3701 of 5 stars	$0.64 +11.5%	$5.00 +684.3%	-57.4%	$17.50M	N/A	N/A	20	High Trading Volume
LPCN Lipocine	2.6699 of 5 stars	$2.05 +0.5%	$15.00 +631.7%	-33.8%	$16.90M	$1.57M	N/A	10	Gap Up
MDCX Medicus Pharma	1.9324 of 5 stars	$0.26 +0.5%	$9.00 +3,302.6%	-88.4%	$16.71M	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:REVB) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Revelation Biosciences (REVB) Competitors

REVB vs. TVRD, CTXR, LPCN, MDCX, and ZIVO

How does Revelation Biosciences compare to Tvardi Therapeutics?

Summary

How does Revelation Biosciences compare to Citius Pharmaceuticals?

Summary

How does Revelation Biosciences compare to Lipocine?

Summary

How does Revelation Biosciences compare to Medicus Pharma?

Summary

How does Revelation Biosciences compare to ZIVO Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REVB vs. The Competition

Revelation Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Revelation Biosciences (REVB) Competitors

REVB vs. TVRD, CTXR, LPCN, MDCX, and ZIVO

How does Revelation Biosciences compare to Tvardi Therapeutics?

Do insiders and institutionals hold more shares of TVRD or REVB?

Do analysts prefer TVRD or REVB?

Which has better earnings and valuation, TVRD or REVB?

Does the media refer more to TVRD or REVB?

Is TVRD or REVB more profitable?

Which has more risk & volatility, TVRD or REVB?

Summary

How does Revelation Biosciences compare to Citius Pharmaceuticals?

Is CTXR or REVB more profitable?

Which has more risk & volatility, CTXR or REVB?

Do analysts rate CTXR or REVB?

Do institutionals and insiders have more ownership in CTXR or REVB?

Which has stronger earnings & valuation, CTXR or REVB?

Does the media prefer CTXR or REVB?

Summary

How does Revelation Biosciences compare to Lipocine?

Is LPCN or REVB more profitable?

Do analysts recommend LPCN or REVB?

Do institutionals & insiders hold more shares of LPCN or REVB?

Does the media refer more to LPCN or REVB?

Which has more risk and volatility, LPCN or REVB?

Which has stronger valuation and earnings, LPCN or REVB?

Summary

How does Revelation Biosciences compare to Medicus Pharma?

Which has stronger earnings and valuation, REVB or MDCX?

Is REVB or MDCX more profitable?

Do institutionals and insiders hold more shares of REVB or MDCX?

Which has more risk and volatility, REVB or MDCX?

Does the media refer more to REVB or MDCX?

Do analysts prefer REVB or MDCX?

Summary

How does Revelation Biosciences compare to ZIVO Bioscience?

Do institutionals & insiders hold more shares of REVB or ZIVO?

Do analysts recommend REVB or ZIVO?

Does the media favor REVB or ZIVO?

Which has more volatility & risk, REVB or ZIVO?

Which has stronger valuation & earnings, REVB or ZIVO?

Is REVB or ZIVO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REVB vs. The Competition

Revelation Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools